Definition, Diagnostic Criteria & Classification

Question	Answer
1. Detail the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus (SLE).	- Mandatory Entry Criterion: Positive ANA titer $\ge 1:80$ on HEp-2 cells (or equivalent positive test). - If entry criterion is met, evaluate weighted criteria across 7 clinical and 3 immunological domains (count only the highest-weighted criterion in each domain): - Constitutional: Unexplained fever $>38.3^\circ\text{C}$ (2 pts). - Hematologic: Leukopenia $<4,000/\mu\text{L}$ (3), Thrombocytopenia $<100,000/\mu\text{L}$ (4), Autoimmune hemolysis (4). - Neuropsychiatric: Delirium (2), Psychosis (3), Seizure (5). - Mucocutaneous: Non-scarring alopecia (2), Oral ulcers (2), Subacute cutaneous or discoid lupus (4), Acute cutaneous lupus / Malar rash (6). - Serosal: Pleural or pericardial effusion (5), Acute pericarditis (6). - Musculoskeletal: Joint involvement / Synovitis (6). - Renal: Proteinuria $>0.5\text{ g/24h}$ (4), Class II or V Lupus Nephritis (8), Class III or IV Lupus Nephritis (10). - Immunological Domains: Antiphospholipid antibodies (2), Low C3 OR low C4 (3), Low C3 AND low C4 (4), SLE-specific antibodies (Anti-dsDNA or Anti-Smith) (6). - Classification Threshold: Total score of $\ge 10$ points classifies as SLE.
2. How does Pediatric-onset SLE (pSLE) differ clinically from Adult-onset SLE?	Compared to adult SLE, pediatric SLE ($<18$ years, representing $15-20\%$ of all SLE cases) is characterized by: 1) More aggressive clinical phenotype with higher initial disease activity scores (SLEDAI). 2) Significantly higher frequency of major organ involvement: Lupus Nephritis ($50-80\%$ vs $30-40\%$), Neuropsychiatric lupus (NPSLE), and severe hematologic cytopenias. 3) Higher cumulative glucocorticoid toxicity: Growth failure, delayed puberty, avascular necrosis, and early cardiovascular atherosclerotic disease. 4) Lower female-to-male ratio prepubertally: Prepubertal ratio is roughly $4:1$, rising to $8-9:1$ after puberty (vs $9-10:1$ in adults).
3. Describe the malar (butterfly) rash of SLE and its differentiating features.	- Appearance: Fixed erythematous, flat or raised rash over the cheeks and bridge of the nose. - Hallmark Differentiating Feature: Strict sparing of the nasolabial folds (in contrast to seborrheic dermatitis, rosacea, or dermatomyositis, which typically involve the nasolabial creases). - Often photosensitive, exacerbated by sun or UV light exposure, and heals without scarring.
4. What are the components of the Antiphospholipid Antibody (aPL) panel in pSLE?	1) Lupus Anticoagulant (LA): Functional clotting assay (prolonged dilute Russell viper venom time [dRVVT] or aPTT that fails to correct with normal plasma mix, but corrects with excess phospholipid). 2) Anticardiolipin Antibodies (aCL): IgG and IgM titers measured by ELISA. 3) Anti-$\beta_2$-Glycoprotein-I Antibodies: IgG and IgM titers measured by ELISA. - Significance: Present in $30-40\%$ of pSLE; predisposes to arterial/venous thrombosis, thrombocytopenia, Libman-Sacks endocarditis, and transverse myelitis.
5. VIVA TRAP: Can a diagnosis of SLE be made if the patient's ANA is negative?	In the 2019 EULAR/ACR criteria, an ANA $\ge 1:80$ is a mandatory entry criterion, without which a patient cannot be classified. However, biologically, true "ANA-negative lupus" occurs in $<1-2\%$ of patients, often associated with isolated Anti-Ro/SSA antibodies, anti-ribosomal P antibodies, or profound proteinuria causing urinary loss of immunoglobulins. If high clinical suspicion persists despite negative ANA on automated bead assays, re-test via immunofluorescence on HEp-2 cells or evaluate under SLICC 2012 criteria (which allows biopsy-proven lupus nephritis with ANA or dsDNA).

Pathophysiology & Complications

Question	Answer
6. Explain the "Defective Efferocytosis" and "Type I Interferon Signature" in pSLE pathogenesis.	- Defective Efferocytosis: Impaired clearance of apoptotic cells by macrophages leads to secondary necrosis, releasing nuclear antigens (dsDNA, histones, ribonucleoproteins - Ro, La, Sm). - Immune Complex Formation: Autoreactive B cells produce high-affinity IgG autoantibodies against nuclear debris. - Plasmacytoid Dendritic Cell Activation: Circulating DNA/RNA-immune complexes are internalized by plasmacytoid dendritic cells (pDCs) via Fc$\gamma$RIIa and bind endosomal Toll-like receptors (TLR7 and TLR9). - Type I Interferon ($IFN\text{-}\alpha$) Hypersecretion: Induces a massive "interferon signature", driving continuous B-cell differentiation, loss of T-regulatory tolerance, and systemic tissue injury.
7. Detail the ISN/RPS (2003) Classification of Lupus Nephritis.	- Class I (Minimal Mesangial): Normal LM, mesangial immune deposits on IF/EM. - Class II (Mesangial Proliferative): Pure mesangial hypercellularity with mesangial immune deposits. - Class III (Focal Lupus Nephritis): Active or inactive endo-/extracapillary glomerulonephritis involving $<50\%$ of all glomeruli (subendothelial deposits). - Class IV (Diffuse Lupus Nephritis): Active or inactive glomerulonephritis involving $\ge 50\%$ of all glomeruli (diffuse subendothelial "wire-loop" deposits; IV-S: segmental, IV-G: global). Most common, most severe form. - Class V (Membranous Lupus Nephritis): Subepithelial immune deposits with diffuse basement membrane thickening (causes severe nephrotic syndrome). - Class VI (Advanced Sclerotic): $\ge 90\%$ globally sclerosed glomeruli without active lesions.
8. VIVA TRAP: Why do serum complement levels (C3, C4) drop during an active SLE flare?	During an active lupus flare (especially proliferative lupus nephritis), massive volumes of circulating immune complexes (dsDNA-anti-dsDNA) deposit within the vascular endothelium and glomerular basement membrane. These complexes continuously activate the classical complement pathway ($C1q \to C4 \to C2 \to C3$). The rate of peripheral complement consumption far outstrips hepatic synthesis, resulting in hypocomplementemia (low C3 and profound low C4). A falling C3/C4 combined with rising anti-dsDNA titers is the classic herald of an impending renal flare!

Guidelines & Management Protocols (EULAR/ACR & CARRA Guidelines)

Question	Answer
9. Why is Hydroxychloroquine (HCQ) recommended for ALL children with SLE?	Unless strictly contraindicated, HCQ ($3-5\text{ mg/kg/day}$, maximum $200-400\text{ mg/day}$) is the foundational anchor drug for every SLE patient because it: 1) Reduces flare rates and prevents organ damage accretion. 2) Improves long-term survival. 3) Lowers thrombosis risk in antiphospholipid-positive patients. 4) Improves lipid profile and glycemic control. - Surveillance: Baseline and annual ophthalmologic screening (visual fields, spectral-domain OCT) after 5 years of use to detect early retinal toxicity (bull's eye maculopathy).
10. Detail the Induction and Maintenance therapy for Class III/IV Proliferative Lupus Nephritis.	1) Induction Phase (Months 0–6): - Pulse Methylprednisolone: $30\text{ mg/kg/day}$ IV (max $1000\text{ mg}$) x 3 days, followed by oral Prednisone ($1-1.5\text{ mg/kg/day}$ tapering), PLUS - Immunosuppression (One of two choices): - Mycophenolate Mofetil (MMF): $800-1200\text{ mg/m}^2/\text{day}$ (or $20-30\text{ mg/kg/day}$) orally divided q12h (preferred first-line in children), OR - IV Cyclophosphamide: Low-dose Euro-Lupus regimen ($500\text{ mg}$ fixed IV q2w x 6 doses) or NIH regimen ($500-750\text{ mg/m}^2$ monthly IV x 6 doses). 2) Maintenance Phase (Years 1–3+): - MMF ($600-800\text{ mg/m}^2/\text{day}$) OR Azathioprine ($2\text{ mg/kg/day}$) plus low-dose oral Prednisone ($<0.1-0.2\text{ mg/kg/day}$) for at least 3 to 5 years.
11. What are the indications for B-cell targeted therapies (Rituximab, Belimumab) in pSLE?	- Belimumab (anti-BAFF / BLyS): FDA/EMA approved for children $\ge 5$ years with active autoantibody-positive SLE; reduces flare rates and corticosteroid dependency. - Rituximab (anti-CD20 monoclonal antibody): $375\text{ mg/m}^2$ weekly x 4 doses or $750-1000\text{ mg/m}^2$ (max $1000\text{ mg}$) on days 1 and 15; indicated for severe refractory lupus nephritis, refractory severe thrombocytopenia/AIHA, or severe neuropsychiatric lupus.

VIVA TRAPs & Counter-Questions

Question

Answer

12. VIVA TRAP: A 14-year-old girl with active SLE and lupus nephritis develops sudden acute breathlessness, hemoptysis, and falling hematocrit. What is the diagnosis and immediate management?

Diffuse Alveolar Hemorrhage (DAH).
A catastrophic, life-threatening complication of pSLE with mortality up to $50\%$.
- Pathophysiology: Pulmonary capillaritis with extensive intra-alveolar extravasation of RBCs.
- Immediate Action:
1) Urgent ICU admission, supplemental oxygen / protective lung mechanical ventilation.
2) Immediate IV Pulse Methylprednisolone: $30\text{ mg/kg/day}$ (max $1000\text{ mg}$) x 3-5 days.
3) Therapeutic Plasma Exchange (Plasmapheresis): Daily 5-7 sessions to clear immune complexes and inflammatory mediators.
4) Emergent B-cell depletion with Rituximab or IV Cyclophosphamide.

13. Counter-Question Chain: "A newborn infant born to a mother with pSLE/Sjögren syndrome develops complete heart block. What is this syndrome, what autoantibodies caused it, and what is the treatment?"

- Diagnosis: Neonatal Lupus Erythematosus (NLE).
- Mechanism: Transplacental crossing of maternal Anti-Ro/SSA and Anti-La/SSB IgG antibodies targeting fetal cardiac conduction tissue, generating autoimmune myocarditis, fibrosis, and permanent destruction of the AV node.
- Cardiac Lesion: Congenital Complete Heart Block (CCHB) is permanent and irreversible; typically requires postnatal permanent epicardial/endocardial pacemaker implantation.
- Cutaneous Lesions: Annular photosensitive erythematous plaques (raccoon eyes) are transient and self-resolve by 6 to 9 months as maternal IgG antibodies clear from the infant's circulation!